Patents by Inventor Martin Ulmann

Martin Ulmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12138266
    Abstract: The present invention relates to preparations of folate salts and their topical use for the treatment of epithelial tissue irritations and skin disorders.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: November 12, 2024
    Assignee: Aprofol AG
    Inventors: Martin Ulmann, Gerd Wiesler, Hans Dutler
  • Patent number: 12048702
    Abstract: Preparations of folate for use in the treatment of eye disorders in the presence of elevated intraocular pressure. Methods of reducing intraocular pressure in a patient having an eye disease.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: July 30, 2024
    Assignee: Aprofol AG
    Inventors: Martin Ulmann, Gerd Wiesler, Josef Flammer
  • Publication number: 20230416253
    Abstract: The invention relates to crystalline folate salts. The salt consists of a folate anion and an organic cation. The folate anion is 5-methyl-(6S)-tetrahydrofolic acid, and the cation is an organic compound which is an alkanolamine selected from the group consisting of choline, N-methylaminoethanol, 2-amino-2-methylpropanol and 2-dimethylaminoethanol.
    Type: Application
    Filed: September 8, 2023
    Publication date: December 28, 2023
    Applicant: APROFOL AG
    Inventors: Martin Ulmann, Gerd Wiesler, Arthur Bodenmüller, Markus Müller
  • Patent number: 11787808
    Abstract: The invention relates to crystalline folate salts. The salt consists of a folate anion and an organic cation. The folate anion is 5-methyl-(6S)-tetrahydrofolic acid, and the cation is an organic compound which is an alkanolamine selected from the group consisting of choline, N-methylaminoethanol, 2-amino-2-methylpropanol and 2-dimethylaminoethanol.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: October 17, 2023
    Assignee: APROFOL AG
    Inventors: Martin Ulmann, Gerd Wiesler, Arthur Bodenmüller, Markus Müller
  • Publication number: 20230277544
    Abstract: The invention relates to amorphous folate salt. The salt consists of a folate anion and an organic cation. The folate anion is selected from the group consisting of 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, (6S)-tetrahydrofolic acid, 5,10-Methylene-(6R)-tetrahydrofolic acid, and its oxidized derivatives JK12A and Mefox, and the cation is an organic compound selected from the group arginine, choline, acetylcholine, 1,1-dimethyl-biguanidin phenylethylbiguanidin, betaine-methylester and dimethylaminoethanol. The cation is an organic compound with a complementary pharmacological activity.
    Type: Application
    Filed: May 12, 2023
    Publication date: September 7, 2023
    Inventors: Martin ULMANN, Gerd WIESLER, Arthur BODENMÜLLER, Markus MÜLLER
  • Patent number: 11690846
    Abstract: The invention relates to amorphous folate salt. The salt consists of a folate anion and an organic cation. The folate anion is selected from the group consisting of 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, (6S)-tetrahydrofolic acid, 5,10-Methylene-(6R)-tetrahydrofolic acid, and its oxidized derivatives JK12A and Mefox, and the cation is an organic compound selected from the group arginine, choline, acetylcholine, 1,1-dimethyl-biguanidin and phenylethylbiguanidin. The cation is an organic compound with a complementary pharmacological activity.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: July 4, 2023
    Inventors: Martin Ulmann, Gerd Wiesler, Arthur Bodenmüller, Markus Müller
  • Publication number: 20230158029
    Abstract: A composition is described comprising at least one folate which is useful in the treatment of ocular diseases linked to elevated retinal venous pressure.
    Type: Application
    Filed: February 26, 2021
    Publication date: May 25, 2023
    Applicant: APROFOL AG
    Inventors: Martin Ulmann, Gerd Wiesler, Josef Flammer
  • Publication number: 20210403471
    Abstract: The invention relates to crystalline folate salts. The salt consists of a folate anion and an organic cation. The folate anion is 5-methyl-(6S)-tetrahydrofolic acid, and the cation is an organic compound which is an alkanolamine selected from the group consisting of choline, N-methylaminoethanol, 2-amino-2-methylpropanol and 2-dimethylaminoethanol.
    Type: Application
    Filed: October 31, 2019
    Publication date: December 30, 2021
    Applicant: APROFOL AG
    Inventors: Martin Ulmann, Gerd Wiesler, Arthur Bodenmüller, Markus Müller (deceased)
  • Publication number: 20210308139
    Abstract: Preparations of folate for use in the treatment of eye disorders in the presence of elevated intraocular pressure. Methods of reducing intraocular pressure in a patient having an eye disease.
    Type: Application
    Filed: August 29, 2019
    Publication date: October 7, 2021
    Applicant: APROFOL AG
    Inventors: Martin Ulmann, Gerd Wiesler, Josef Flammer
  • Publication number: 20210267982
    Abstract: The present invention relates to preparations of folate salts and their topical use for the treatment of epithelial tissue irritations and skin disorders.
    Type: Application
    Filed: July 1, 2019
    Publication date: September 2, 2021
    Inventors: Martin ULMANN, Gerd WIESLER, Hans DUTLER
  • Publication number: 20200261460
    Abstract: The invention relates to amorphous folate salt. The salt consists of a folate anion and an organic cation. The folate anion is selected from the group consisting of 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, (6S)-tetrahydrofolic acid, 5,10-Methylene-(6R)-tetrahydrofolic acid, and its oxidized derivatives JK12A and Mefox, and the cation is an organic compound selected from the group arginine, choline, acetylcholine, 1,1-dimethyl-biguanidin and phenylethylbiguanidin. The cation is an organic compound with a complementary pharmacological activity.
    Type: Application
    Filed: August 29, 2018
    Publication date: August 20, 2020
    Inventors: Martin ULMANN, Gerd WIESLER, Arthur BODENMÜLLER, Markus MÜLLER
  • Patent number: 9642853
    Abstract: The administration of leucovorin as well as other active, reduced folates is useful as an antidote to drugs which act as folic acid antagonists and in combination chemotherapy with 5-FU. The most often used calcium salts of the folates have a low solubility in water and form almost insoluble degradation products. Therefore, aqueous solutions are unstable and precipitates result. Precipitates in injectable products present an unacceptable safety risk to patients. Stable high strength pharmaceutical aqueous compositions are formed containing calcium salts, magnesium or zinc salts of the reduced folates leucovorin, (6R,S)-tetrahydrofolic acid, (6S)-tetrahydrofolic acid, 5,10-methylene-(6R,S)-tetrahydrofolate, 5,10-methylene-(6R)-tetrahydrofolate, 5-methyl-(6R,S)-tetrahydrofolate or 5-methyl-(6S)-tetrahydrofolate and one or more of the compounds sodium gluconate, potassium gluconate, glycerophosphate disodium salt or glycerophosphate dipotassium salt.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: May 9, 2017
    Assignee: APROFOL AG
    Inventor: Martin Ulmann
  • Patent number: 9301922
    Abstract: The administration of levoleucovorin is useful as an antidote to drugs which act as folic acid antagonists and in combination chemotherapy with 5-FU. The most often used calcium salt of levoleucovorin has a limited solubility in water and forms almost insoluble degradation products. Therefore aqueous solutions are unstable and precipitates are resulting. Precipitates in injectable products present an unacceptable safety risk to patients. Stable high strength pharmaceutical aqueous compositions containing calcium salts, magnesium or zinc salts of levoleucovorin and one or more of the compounds sodium gluconate, potassium gluconate, glycerophosphate disodium salt or glycerophosphate dipotassium salt are disclosed.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: April 5, 2016
    Assignee: APROFOL AG
    Inventor: Martin Ulmann
  • Publication number: 20160081926
    Abstract: The administration of levoleucovorin is useful as an antidote to drugs which act as folic acid antagonists and in combination chemotherapy with 5-FU. The most often used calcium salt of levoleucovorin has a limited solubility in water and forms almost insoluble degradation products. Therefore aqueous solutions are unstable and precipitates are resulting. Precipitates in injectable products present an unacceptable safety risk to patients. Stable high strength pharmaceutical aqueous compositions containing calcium salts, magnesium or zinc salts of levoleucovorin and one or more of the compounds sodium gluconate, potassium gluconate, glycerophosphate disodium salt or glycerophosphate dipotassium salt are disclosed.
    Type: Application
    Filed: April 30, 2014
    Publication date: March 24, 2016
    Applicant: APROFOL AG
    Inventor: Martin ULMANN
  • Publication number: 20160074402
    Abstract: The administration of leucovorin as well as other active, reduced folates is useful as an antidote to drugs which act as folic acid antagonists and in combination chemotherapy with 5-FU. The most often used calcium salts of the folates have a low solubility in water and form almost insoluble degradation products. Therefore, aqueous solutions are unstable and precipitates result. Precipitates in injectable products present an unacceptable safety risk to patients. Stable high strength pharmaceutical aqueous compositions are formed containing calcium salts, magnesium or zinc salts of the reduced folates leucovorin, (6R,S)-tetrahydrofolic acid, (6S)-tetrahydrofolic acid, 5,10-methylene-(6R,S)-tetrahydrofolate, 5,10-methylene-(6R)-tetrahydrofolate, 5-methyl-(6R,S)-tetrahydrofolate or 5-methyl-(6S)-tetrahydrofolate and one or more of the compounds sodium gluconate, potassium gluconate, glycerophosphate disodium salt or glycerophosphate dipotassium salt.
    Type: Application
    Filed: April 30, 2014
    Publication date: March 17, 2016
    Applicant: APROFOL AG
    Inventor: Martin ULMANN
  • Publication number: 20100179095
    Abstract: This invention relates to the use of folates for producing a pharmaceutical preparation suitable for the prevention and treatment of inflammation and of diseases associated with inflammation, particularly for influencing the inflammation markers C-reactive protein (CRP) and serum amyloid A protein (SAA). The clinical areas of application are all anomalies of the CRP and SAA levels.
    Type: Application
    Filed: January 29, 2010
    Publication date: July 15, 2010
    Inventors: Thomas MUELLER, Rudolf Moser, Martin Ulmann
  • Publication number: 20060063768
    Abstract: This invention relates to the use of folates for producing a pharmaceutical preparation suitable for the prevention and treatment of inflammation and of diseases associated with inflammation, particularly for influencing the inflammation markers C-reactive protein (CRP) and serum amyloid A protein (SAA). The clinical areas of application are all anomalies of the CRP and SM levels.
    Type: Application
    Filed: February 24, 2003
    Publication date: March 23, 2006
    Inventors: Thomas Mueller, Rudolf Moser, Martin Ulmann
  • Patent number: 6596721
    Abstract: Pure and extremely stable crystalline (6R)-tetrahydrofolic acids, absolutely inert even when exposed to air and elevated temperature without stabilizers being added, are prepared by a crystallization process at a pH of ≧2.
    Type: Grant
    Filed: January 8, 2001
    Date of Patent: July 22, 2003
    Assignee: Eprova AG
    Inventors: Hans Rudolf Müller, Martin Ulmann, Rudolf Moser, Thomas Ammann
  • Patent number: 6271374
    Abstract: Pure and extremely stable crystalline (6S)- and (6R)-tetrahydrofolic acids, absolutely inert even when exposed to air and elevated temperature without stabilizers being added, are prepared by a crystallization process at a pH of ≧3.5 for the preparation of crystalline (6S)-tetrahydrofolic acid and at a pH of ≧2 for the preparation of crystalline (6R)-tetrahydrofolic acid.
    Type: Grant
    Filed: January 26, 1998
    Date of Patent: August 7, 2001
    Assignee: Eprova AG
    Inventors: Hans Rudolf Müller, Martin Ulmann, Rudolf Moser, Thomas Ammann
  • Publication number: 20010002398
    Abstract: Pure and extremely stable crystalline (6S)- and (6R)-tetrahydrofolic acids, absolutely inert even when exposed to air and elevated temperature without stabilizers being added, are prepared by a crystallization process at a pH of ≧3.5 for the preparation of crystalline (6S)-tetrahydrofolic acid and at a pH of ≧2 for the preparation of crystalline (6R)-tetrahydrofolic acid.
    Type: Application
    Filed: January 8, 2001
    Publication date: May 31, 2001
    Applicant: EPROVA AKTIENGESELLSCGAFT
    Inventors: Hans Rudolf Muller, Martin Ulmann, Rudolf Moser, Thomas Ammann